Oct 6, 2025 · Harrow is redefining the standard of care in eyecare with a portfolio of trusted, high-value pharmaceutical solutions that deliver proven safety, efficacy, and affordability.

Harrow, a leading provider of ophthalmic disease management solutions in North America, was founded with a commitment to deliver safe, effective, accessible, and affordable medications …

Mar 17, 2025 · Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic …

SAN DIEGO , May 5, 2016 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary …

Harrow INC SEC filing: Form 8-K iXBRL on 09/09/2025 (0001493152-25-012840).

www.harrow.com

Harrow helps eyecare professionals preserve the gift of sight by making its portfolio of pharmaceutical products accessible and affordable to millions of patients each year. For more …

Harrow was established with the core principle of delivering accessible eyecare solutions to both eyecare providers and patients. We are dedicated to helping eligible patients access the …

Harrow INC SEC filing: Form 10-Q on 11/13/2023 (0001493152-23-040563).

Harrow Health currently holds equity positions in Eton Pharmaceuticals, Surface Ophthalmics, and Melt Pharmaceuticals, which are all former subsidiaries of Harrow Health.